Abstract
Antibody-drug conjugates (ADCs) are advance biologic molecules in which chemical drugs are bound to an antibody targeting a specific antigen on the surface of cells. ADCs are a new kind of therapeutic agents in the treatment of various cancers. As they are the combination of an antibody and a small molecule drug, they present unique challenges for analytical characterization. Attributes from both the small and large molecule components should be considered as quality attributes. This chapter will present the current approaches in analytical methodologies used for ADC characterization.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wilson R. A personal perspective of the development and validation of a phase-specific antibody–drug conjugate cytotoxicity potency assay. Bioanalysis. 2013;5(9):1083–97.
Miller K, Mullan A, Novick S, Raju T. Use of design of experiment (DOE) for optimization of ADC potency assays. Am Pharm Rev. 2017;
Roberts CJ. Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol. 2014;32(7):372–80.
Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. Classification and characterization of therapeutic antibody aggregates. J Biol Chem. 2011;286:25118–33.
Strehl R, Rombach-Riegraf V, Diez M, Egodage K, Bluemel M, Jeschke M, Koulov AV. Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: a novel multiparametric image filter for sub-visible particles in microflow imaging analysis. Pharm Res. 2012;29:594–602.
Narhi LO, Corvari V, Ripple DC, Afonina N, Cecchini I, Defelippis MR, Garidel P, Herre A, Koulov AV, Lubiniecki T, Mahler HC, Mangiagalli P, Nesta D, Perez-Ramirez B, Polozova A, Rossi M, Schmidt R, Simler R, Singh S, Spitznagel TM, Weiskopf A, Wuchner K. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: part 1, considerations and strategy. J Pharm Sci. 2015;104(6):1899–908.
Martos A, Koch W, Jiskoot W, Wuchner K, Winter G, Friess W, Hawe A. Trends on analytical characterization of polysorbates and their degradation products in biopharmaceutical formulation. J Pharm Sci. 2017;106:1722–35.
Guo J, Kumar S, Prashad A, Starkey J, Singh SK. Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol-maleimide chemistry. Pharm Res. 2014;31(7):1710–23.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Fischmann, S. et al. (2020). Chapter 10: Analytical Methods for Antibody Drug Conjugate Characterization. In: Jameel, F., Skoug, J., Nesbitt, R. (eds) Development of Biopharmaceutical Drug-Device Products. AAPS Advances in the Pharmaceutical Sciences Series, vol 35. Springer, Cham. https://doi.org/10.1007/978-3-030-31415-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-31415-6_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31414-9
Online ISBN: 978-3-030-31415-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)